LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

被引：0
|
作者：
Jackson, D. [1 ]
Lee, J. M. [2 ]
Adams, J. [1 ]
Gordois, A. [1 ]
机构：
[1] IMS Hlth, St Leonards, NSW, Australia
[2] Sanofi Aventis Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74342-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [41] Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide
    Aristidis Polyzos
    C. Kosmas
    N. Tsavaris
    C. Markopoulos
    N. Kalahanis
    O. Papadopoulos
    T. Arnaouti
    P. P. Sfikakis
    Clinical Drug Investigation, 2000, 19 : 349 - 355
  • [42] Cost-effectiveness of adjuvant chemotherapy for node plus breast cancer: modeling the downstream effects of adjuvant TAC vs FAC: docetaxel (T), adriamycin (A), cyclophosphamide (C) compared to 5-fluorouracil (F) A C.
    Au, HJ
    Golmohammadi, K
    Chia, S
    Verma, S
    Younis, T
    Chin, C
    Jacobs, P
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S218 - S218
  • [43] Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
    Loesch, David
    Greco, F. Anthony
    Senzer, Neil N.
    Burris, Howard A.
    Hainsworth, John D.
    Jones, Stephen
    Vukelja, Svetislava J.
    Sandbach, John
    Holmes, Frankie
    Sedlacek, Scot
    Pippen, John
    Lindquist, Deborah
    McIntyre, Kristi
    Blum, Joanne L.
    Modiano, Manuel R.
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    Robert, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2958 - 2965
  • [44] Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer
    Yu, Joanne L.
    Chan, Kelvin
    Kurin, Michael
    Pasetka, Mark
    Kiss, Alex
    Sridhar, Srikala S.
    Warner, Ellen
    BREAST JOURNAL, 2015, 21 (06): : 658 - 664
  • [45] Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197
    Goldstein, Lori J.
    O'Neill, Anne
    Sparano, Joseph A.
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Davidson, Nancy E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4092 - 4099
  • [46] Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast Group
    von Minckwitz, G
    Raab, G
    Caputo, A
    Schütte, M
    Hilfrich, F
    Blohmer, JU
    Gerber, B
    Costa, SD
    Merkle, E
    Eidtmann, H
    Lampe, D
    Jackisch, C
    du Bois, A
    Kaufmann, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2676 - 2685
  • [47] A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Rapoport, B. L.
    Moodley, S. D.
    Jacobs, C.
    Pienaar, R.
    Fourie, S.
    Szpak, W. M.
    BREAST, 2007, 16 : S64 - S64
  • [48] COST EFFECTIVENESS OF ADJUVANT CYCLOPHOSPHAMIDE CONTAINING REGIMES TO AT IN THE TREATMENT OF BREAST CANCER IN GERMANY
    Walter, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 121
  • [49] Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - the Hong Kong experience
    Yau, Tsz-Kok
    Ng, Ting-Ying
    Soong, Inda Sung
    Choi, Chi-Wai
    Lam, ka-On
    Ng, Alice Wan-Ying
    Lee, Anne Wing-Mui
    Tung, Yuk
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 123 - 128
  • [50] Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
    Gradishar, WJ
    Wedam, SB
    Jahanzeb, M
    Erban, J
    Limentani, SA
    Tsai, KT
    Olsen, SR
    Swain, SM
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1297 - 1304
12345